For sales

📢Highlights from the past week in the world of pharma and healthcare! 🗞️👀

Celltrion (FDA) Celltrion’s OMLYCLO® receives FDA approval as the First and Only Interchangeable XOLAIR® Biosimilar H. Lundbeck A/S (Approval, EC) European Commission Approves Lundbeck's Rxulti® for Schizophrenia in Adolescents Aged 13 and Above Amgen (Positive Data) Amgen's UPLIZNA® Shows Significant 52-Week Improvement in Generalized Myasthenia Gravis Patients BioCity Biopharma (Collaboration) BioCity Biopharmaceutics Collaborates with Merck to Evaluate BC3195 & KEYTRUDA® Combination in Solid Tumors
Download
Vyuhpharma Logo (1)-pdf (1)

The Pharma BI division of

Vyuhgenics Inc.

Henderson, Nevada, USA – 89014

Connect with us

Please fill in the information below, and we'll get back to you.